Βιογραφικό

Καθηγήτρια Νευρολογίας Παν/μίου Marburg, Γερμανία
Υπεύθυνη τμήματος Πάρκινσον και Κινητικών Διαταραχών Νοσοκομείου "ΥΓΕΙΑ"
Εξειδικευμένη στη Νόσο Πάρκινσον & άλλες Κινητικές Διαταραχές, UCL, Αγγλία.
Έκτακτη αναπληρώτρια καθηγήτρια στο Ευρωπαϊκό Πανεπιστήμιο Κύπρου

►

Εκπαίδευση & Ακαδημαϊκοί Τίτλοι

2017 - σήμερα Καθηγήτρια Νευρολογίας, Παν/μίου Marburg, Γερμανία
2019 - σήμερα έκτακτη Αναπληρώτρια Καθηγήτρια Ευπρωπαϊκό Πανεπιστήμιο Κύπρου
2013-2017 Επίκουρη καθηγήτρια Νευρολογίας, Παν/μίου Marburg, Γερμανία
10/2010-02/2013 Eξειδίκευση στη νόσο Πάρκινσον και Κινητικές Διαταραχές (UCL, Sobell Dept. of Motor Neurosciences and Movement Disorders, Queen Square, London, UK)
01/2005 – 09/2009 Διδακτορική διατριβή, Tίτλος “Coenzyme Q10 in progressive supranuclear palsy: a randomized, double-blind, placebo-controlled study” (Philipps University, Marburg, Germany, «άριστα με διάκριση», summa cum laude)
01/2005-10/2010 Ειδικότητα Νευρολογίας: Philipps-University, Marburg, Γερμανία
2005-2010 Ειδικά εξωτερικά ιατρεία για νόσο Πάρκινσον και Κινητικές Διαταραχές
2005-2010 Ειδικά εξωτερικά ιατρεία για άτυπα παρκινσονικά σύνδρομα
2009-2010 Ειδικά εξωτερικά ιατρεία για ενδομυϊκές ενέσεις αλλαντικής τοξίνης (http://www.hygeia.gr σε δυστονίες, σπαστικότητα και υπεριδρωσία με ηλεκτρομυογραφικό έλεγχο (πιστοποίηση από την γερμανική εταιρεία ΒοΝΤ)
2007-2009 Μονάδα εντατικής θεραπείας για νευρολογικές νόσους (εκπαίδευση σε επείγουσα ιατρική, διασωληνώσεις, τοποθέτηση κεντρικών γραμμών)
2009-2010 Εκπαίδευση στην ηλεκτροφυσιολογία, ΕΜΓ, ΕΝΓ, προκλητά δυναμικά, ΕΕΓ
2001-2002 Erasmus exchange programme: Πανεπιστήμιο Freiburg, Γερμανία
1996-2002 MD, Πτυχίο Ιατρικής: Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Τμήμα Ιατρικής

ΕΚΠΑΙΔΕΥΤΙΚΗ ΕΜΠΕΙΡΙΑ
ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΠΡΟΠΤΥΧΙΑΚΟΥΣ ΚΑΙ ΜΕΤΑΠΤΥΧΙΑΚΟΥΣ ΦΟΙΤΗΤΕΣ

2005-2010 Μαθήματα σε προπτυχιακούς φοιτητές ως ειδικευόμενη στην Νευρολογική κλινική Παν/μιου Philipps, Marburg, Γερμανία (20 διδακτικές ώρες κάθε εξάμηνο)
2010-2013 Μαθήματα σε μεταπτυχιακούς φοιτητές ως fellow στις Κινητικές Διαταραχές, στο UCL, UK
2013- έως σήμερα: Μαθήματα σε προπτυχιακούς φοιτητές ως καθηγήτρια στην Νευρολογική κλινική
Παν/μιου Philipps, Marburg, Γερμανία (τουλάχιστον 16 διδακτικές ώρες κάθε εξάμηνο)
2013-2017: Μαθήματα σε προπτυχιακούς φοιτητές και ειδικευόμενους ως συνεργάτης και υπότροφος B’ Νευρολογική κλινική, Αττικό νοσοκομείο, ΕΚΠΑ, Αθήνα
2017- σήμερα: Μαθήματα σε προπτυχιακούς φοιτητές και ειδικευόμενους ως συνεργάτης και υπότροφος A’ Νευρολογική κλινική, Αιγινήτειο νοσοκομείο, ΕΚΠΑ, Αθήνα

ΟΡΓΑΝΩΤΡΙΑ ΕΚΠΑΙΔΕΥΤΙΚΩΝ ΕΚΔΗΛΩΣΕΩΝ

Course Director and Scientific Organizing Committee, Genetics of Parkinson’s disease and atypical parkinsonian syndromes in clinical practise, Movement Disorders Society (MDS), Athens, October 3-4, 2014
200 years Parkinson’s disease: 200 years of progress, Royal Olympic hotel, September 2017
1st Autumn School, European Academy of Neurology (EAN), Loutraki, Greece, November 2018
2nd Autumn School, European Academy of Neurology (EAN), Loutraki, Greece, October 2019

►

Διδακτορική Διατριβή

►

Μέλος Εταιριών, Συντακτικής Επιτροπής Περιοδικών

►

Επαγγελματική Προϋπηρεσία

►

Κλινικό & Ερευνητικό Ενδιαφέρον

►

Διακρίσεις & Βραβεία

►

Ομιλίες σε διεθνή συνέδρια (selected)

Atypical Parkinson Syndromes: Practical Therapy. 6th German Parkinson Congress, 2009, Marburg, Germany
Effects of coenzyme Q10 in progressive supranuclear palsy. 23. Greek neurology congress, May 2009,Thessaloniki, Greece
Differential Diagnosis of atypical parkinsonian conditions: British-Turkish Meeting, Queen Square, April 2012
Progressive supranuclear palsy: Treatment. Teaching Course, International Movement Disorders Congress,Dublin, Ireland, 2012
PSP diagnostics. 1st German PSP meeting, Munich, Germany, 2012
The spectrum of cranio-cervical dystonias,International Movement Disorders Congress, Sydney, Australia, 2013
Atypical parkinsonism : Summer school for Movement Disorders, MDS, London, July 2013
The differential diagnosis of vascular parkinsonism with Parkinson’s disease and atypical parkinsonism, International Congress of Vascular Dementia, Athens, 2013
PSP treatment: 18th International Movement Disorders Society Congress, Stockholm, June, 2014
Other hereditary parkinsonian syndromes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
Genetic PSP-, CBD-, MSA- look alikes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
PSP-look alikes: 50 Years of progressive supranuclear palsy; MDS, Munich, Germany, 9-10th October 2014
Update on PSP: Annual Parkinson Meeting; Ancona, Italy, 16-17th October 2014
The non-motor syndrome of dystonia: International Congress on Non-motor dysfunction in Parkinson's disease and related disorders (NMDPD), Nice, France, 4-7th December 2014
Movement Disorders in the Media. 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015
Invited expert in Video Challenge, 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015
Update on atypical parkinsonism, Deutsche Gesselschaft für Neurologie (DGN) Kongress, Düsseldorf, October, 2015
Interventions in PSP: World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
Unusual Movement Disorders, Video Session. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
PSP subtypes and phenotypes. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
Atypical Parkinsonism, Parkinson’s congress, Marburg, Germany, 3-5 March 2016
Spasticity-parkinsonism syndromes, Movement Disorders Scholl, Ravello, Italy, 14-16 April, 2016
New classification of dystonia, Greek Movement Disorders School, Thessaloniki, Greece, April 2016
Atypical parkinsonism, MDS Movement Disorders Teaching Course, Kosice, Slovakia, 13-15 May 2016
Update on atypical parkinsonism, 2nd European Academy of Neurology Congress, Copenhagen, Denmark, 29-31 May 2016
Atypical parkinsonism, Academy of Neurosciences Movement Disorders School, Ioannina, Greece, 3-4 June 2016
Movement Disorders Grand rounds, 20th international congress of Parkinson's disease and Movement Disorders, 19-23 June 2016
New therapies in parkinsonism, International meeting of the Cyprus Neurological Society Nicosia, Cyprus 12-14 November 2016
Essential and other tremor syndromes, International meeting of the Cyprus Neurological Society, Nicosia, Cyprus 12-14 November 2016
Is imaging very useful in the diagnosis of parkinsonism? 11th World congress on controversies in Neurology, 25-29 March 2017
The role of gastrointestinal system in the pathogenesis of PD. 11th World congress on controversies in Neurology, 25-29 March 2017
Is essential tremor a single entity? 11th World congress on controversies in Neurology, 25-29 March 2017
‘Freezing of gait in parkisnon’s disease’, Movement Disorders school, Corfu, Greece, May 2017
Atypical Parkinsonism, Movement Disorders school, Corfu, Greece, May 2017
Distinguishing PSP, MSA and CBS, 2nd EAN congress, Amsterdam, June, 2017
Atypical parkinsonism, Greek Neurology congress, Kalamata, June 2017
Pitfalls in MSA Diagnosis: 20 years a-synuclein, Vravrona, Athens, September 2017
The role of SPECT in the differential diagnosis of parkinsonism, Athens, December 2017
Atypical parkinsonism, Berner Movement Disorders Course, Bern, Switzerland, March 2018
Treatment of non-motor symptoms in advanced Parkinson’s Disease, 4th EAN congress, Lisbon, June 2018
Movement disorders videos, IAPRD, International Congress on Parkinson’s disease and related disorders, 19-22 August 2018, Lyon, France
Atypical parkinsonism: PSP/CBD, 22st International Congress of Parkinson’s disease and Movement Disorders, Hong Kong, October 2018
An approach to tremor: 1st European Academy of Neurology Autumn School, 8-11 November 2018, Loutraki, Greece
The new clinical criteria for PSP, 8th ACNE Movement Disorders course, November 2018, Pilion, Greece
Phenotypic spectrum of PSP; 4th European Academy of Neurology Congress, Oslo, June 2019
Atypical parkinsonism: Phenotypic spectrum, 24th World Congress of Neurology, Dubai, Oct 2019
Approach to hyperkinetic movement disorders: Tremor/Myoclonus, 24th World Congress of Neurology, Dubai, Oct 2019

►

Βιβλία

►

Δημοσιεύσεις

Pubmed indexed:156; h-index: 41; citations: 6164

1. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008 May 15;23(7):942-9.
2. Eggert K, Schrader C, Hahn M, Stamelou M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008 May-Jun;31(3):151-66
3. Strzelczyk A, Möller JC, Stamelou M, et al. [Atypical Parkinson syndromes]. Nervenarzt. 2008 Oct;79(10):1203-20.
4. Hattingen E, Lanfermann H, Menon S, Neumann-Haefelin T, de Rochement RD, Stamelou M, et al. Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid progressive supranuclear palsy. J Cereb Blood Flow Metab. 2009 Apr;29(4):861-70.
5. Stamelou M, Pilatus U, Reuss A, et al. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2009 Apr;29(4):861-70.
6. Stamelou M, Matusch A, Elmenhorst D, et al. Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy. Mov Disord. 2009 Jun 15;24(8):1170-5.7. Knake S, Belke M, Menzler K, Pilatus U, Eggert KM, Oertel WH, Stamelou M, Höglinger GU. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Mov Disord. 2010 Jul 15;25(9):1232-8.
8. Stamelou M, de Silva R, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010 Jun;133(Pt 6):1578-90.
9. Arias-Carrión O, Stamelou M, et al. Dopaminergic reward system: a short integrative review. Int Arch Med. 2010 Oct 6;3:24.
10. Arias-Carrión O, Stamelou M. Targeting the orexin system: a new approach for treating insomnia. CNS Neurol Disord Drug Targets. 2010 Dec;9(6):667.
11. Winter Y, Stamelou M, et al. Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol. 2011 Oct;258(10):1827-34.
12. Stamelou M, Christ H, Reuss A, et al Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Mov Disord. 2011 Apr;26(5):901-5
13. Stamelou M, Knake S, et al. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol. 2011 Apr;258(4):549-58
14. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord. 2011 Jun;26(7):1243-50. Stamelou, March 2015
15. Stamelou M, et al. Characteristic constant groaning in late stage progressive supranuclear palsy: a case report. Parkinsonism Relat Disord. 201Aug;17(7):575-6
16. Stamelou M, et al. Ability to cycle despite severe freezing of gait in atypical parkinsonism in Fahr's syndrome. Mov Disord. 2011 Sep;26(11):2141-2.
17. Winter Y, Spottke AE, Stamelou M, et al. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis. 2011;8(6):438-46.
18. Höglinger GU, PSP Genetics Study Group et al. Identification of common variants influencing risk of the Tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jun 19;43(7):699-705.
19. Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2011 Sep
20. Stamelou M, Edwards MJ, Espay AJ, et al. Movement disorders on YouTube--caveat spectator. N Engl J Med. 2011 Sep 22;365(12):1160-1
21. Stamelou M, Dohmann H, Brebermann J, et al. Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. Parkinsonism Relat Disord. 2011 Nov 29
22. Unger MM, Möller JC, Mankel K, Schmittinger K, Eggert KM, Stamelou M, et al. Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test. Mov Disord. 2011 Dec;26(14):2559-63
23. Stamelou M, Saifee TA, Edwards MJ, Bhatia KP. Psychogenic palatal tremor may be under-recognized: reappraisal of a large cases series. Mov Disord. 2012 Mar 20. doi: 10.1002/mds.24948
24. Batla A, Stamelou M, Bhatia KP. Treatment of focal dystonia. Curr Treat Options Neurol. 2012 Jun;14(3):213-29
25. Stamelou M, Alonso-Canovas A, Bhatia KB. Dystonia in corticobasal degeneration: a review of 404 pathologically proven cases. Mov Disord, 2012 May;27(6):696-702
26. Stamelou M, Mencacci NE, et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology, 2012 Jul 31;79(5):435-41
27. Gardiner A, Bhatia K, Stamelou M, et al., PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology, 2012 Nov 20;79(21):2115-21.
28. Stamelou M, Plazzi G, et al. The distinct movement disorder in NMDA-antibodies encephalitis may be related to Status Dissociatus: a hypothesis. Mov Disord, 2012
29. Stamelou M, Bhatia KP. A new treatable genetic disorder of manganese metabolism causing dystonia-parkinsonism and cirrhosis: the “new” Wilson’s disease? Mov Disord, 2012 Jul;27(8):962
30. Stamelou M, Edwards MJ, Bhatia KP. Late onset rest-tremor in DYT1 dystonia. Parkinsonism and relat disord, in press
31. Stamelou M, Tuschl K, et al. Dystonia with brain manganese accumulation due to SLC30A10 mutations: a new treatable disorder. Mov Disord, 2012 Aug 23. doi: 10.1002/mds.25138
32. Xiromerisiou G, Houlden H, Scarmeas N, Stamelou M, et al. THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. Mov Disord, 2012 Aug 17. doi: 10.1002/mds.25146
33. Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. J Neurol Neurosurg Psychiatry. 2012 Sep 19, in press
34. Stamelou M, et al. Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation.J Neurol. 2013 Feb;260(2):656-60.
35. Aguirregomozcorta M, Stamelou M, et al. Patients with rest-tremor and scans with ipsilateral dopaminergic deficit.J Neurol. 2012 Nov 30. [Epub ahead of print]
36. Charlesworth G, Plagnol V, Holmström KM, Bras J, Sheerin UM, Preza E, Rubio-Agusti I, Ryten M, Schneider SA, Stamelou M, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet. 2012 Dec 7;91(6):1041-50.
37. Marx S, Respondek G, Stamelou M, et al. Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. Front Behav Neurosci. 2012;6:88.
38. Batla A, Stamelou M, et al. Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Mov Disord. 2013 Feb 5.
39. Batla A, Stamelou M, et al. Functional movement disorders are not uncommon in the elderly. Mov Disord. 2013 Feb 15.
40. Stamelou M et al., Progressive ataxia and palatal tremor associated with dense pontine calcification: A unique case. Mov Disord. In press Stamelou, March 2015 4
41. Krismer F, Duerr S, Minnerop M, Klockgether T, Stamelou M, et al. [MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy : Validation of the German translation]. Nervenarzt. 2013 Jun;84(6):709-14.
42. Batla A, Stamelou M, et al. Markedly asymmetric presentation in multiple system atrophy. Parkinsonism Relat Disord. 2013 Jun 6.
43. Stamelou M, et al. Dystonic opisthotonus: A "red flag" for neurodegeneration with brain iron accumulation syndromes?Mov Disord. 2013 Jun 4.
44. Stamelou M, Quinn NP, Bhatia KP. "Atypical" atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-A diagnostic guide.Mov Disord. 2013 May 29
45. Stamelou M, Christodoulou C, Stefanis L. Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study.Mov Disord. 2013 Apr 15;28(5):689.
46. Stamelou M, et al. Familial psychogenic movement disorders.Mov Disord. 2013 Apr 8.
47. Stamelou M. Commentary for "Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease".Mov Disord. 2013 Mar;28(3):293-4.
48. Rubio-Agusti I, Pareés I, Kojovic M, Stamelou M, et al. Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort. Parkinsonism Relat Disord. 2013 Jun;19(6):634-8.
49. Stamelou M, Hoglinger GU. Atypical parkinsonism : an update, Curr Op Neurol, in press
50. Charlesworth G, Mohire MD, Schneider SA, Stamelou M, et al. Neurology. 2013 Sep 24;81(13):1148-51
51. Ganos C, Aguirregomozcorta M, Batla A, Stamelou M, et al. Psychogenic paroxysmal movement disorders - Clinical features and diagnostic clues. Parkinsonism Relat Disord. 2014 Jan;20(1):41-6
52. Mok KY, Schneider SA, Trabzuni D, Stamelou M, et al. Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. Mov Disord. 2013 Nov 13.
53. Stamelou M, Charlesworth G, et al. The phenotypic spectrum of DYT24 due to ANO3 mutations. Mov Disord. 2014 Jan 17.
54. Obeso J, Rodriguez-Oroz M, Stamelou M et al. The expanding universe of basal ganglia disorders. The Lancet, 2014, in press
55. Sheerin UM, Schneider SA, Stamelou M et al. Generalized dystonia in ALS2 mutations carriers. Neurology, 2014, in press
56. Macerollo A, Perry R, Stamelou M et al. Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty, Eur J Neurol, in press
57. PSP Study Group, A Phase 2 Trial of the GSK-3 Inhibitor Tideglusib in Progressive Supranuclear Palsy, Mov Disord, 2014, in press
58. PSP Study Group, Tideglusib Reduces Progression of Brain Atrophy in Progressive Supranuclear Palsy in a Randomized Trial, Mov Disord, 2014, in press59. Stamelou M. Commentary on familial gluten ataxia, Mov Disord 2014, in press
60. Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ. The expanding universe of disorders of the basal ganglia. Lancet. 2014 Aug 9;384(9942):523-31.
61. Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, et al; International Parkinson’s Disease Genomics Consortium and UCL-exomes consortium. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain. 2014 Sep;137(Pt 9):2480-92. doi: 10.1093/brain/awu179.
62. Sadnicka A, Teo JT, Kojovic M, Pareés I, Saifee TA, Kassavetis P, Schwingenschuh P, Katschnig-Winter P, Stamelou M, et al. All in the blink of an eye: new insight into cerebellar and brainstem function in DYT1 and DYT6 dystonia. Eur J Neurol. 2014 Jul 18
63. Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, et al. Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry. 2014 Sep 22
64. Stamelou M, Sheerin UM, Wood N, Bhatia KP. The entity of parkinsonism and associated lipomatosis. Neurology. 2014 Oct 28;83(18):1673-4
65. Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study. Mov Disord. 2014 Oct 28. doi: 10.1002/mds.26018.
66. Respondek G*, Stamelou M*, et al; for the Movement Disorder Society-endorsed PSP Study GroupThe phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Mov Disord. 2014 Nov 5. doi: 10.1002/mds.26054.
67. Stamelou M, Bhatia KP. Atypical Parkinsonism: Diagnosis and Treatment. Neurol Clin. 2015 Feb;33(1):39-56 Stamelou, March 2015 5
68. Erro R, Hersheson J, Ganos C, Mencacci NE, Stamelou M, et al. H-ABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations?Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26129.
69. Stamelou M, Boxer AL. Disease-Modifying Treatments for Progressive Supranuclear Palsy, Mov Disord Clin Practice
70. Stamelou M, Pilatus U, Reuss A, Respondek G, Knake S, Oertel WH, Höglinger GU. Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. Parkinsonism Relat Disord. 2015 Mar 12
71. Charlesworth G, Angelova PR, Bartolomé-Robledo F, Ryten M, Trabzuni D, Stamelou M, Abramov AY, Bhatia KP, Wood NW. Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia. Am J Hum Genet. 2015 Mar 17
72. Stamelou M, Pilatus U, Reuss A, Respondek G, Knake S, Oertel WH, Höglinger GU.
Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. Parkinsonism Relat Disord. 2015 May;21(5):533-5.
73. Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP.What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):319-23
74. Mencacci NE, Erro R, Wiethoff S, Hersheson J, Ryten M, Balint B, Ganos C, Stamelou M, Quinn N, Houlden H, Wood NW, Bhatia KP. ADCY5 mutations are another cause of benign hereditary chorea. Neurology. 2015 Jul 7;85(1):80-8.
75. Manohar SG, Chong TT, Apps MA, Batla A, Stamelou M, Jarman PR, Bhatia KP, Husain M. Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. Curr Biol. 2015 Jun 29;25(13):1707-16
76. Antelmi E, Stamelou M, Liguori R, Bhatia KP.Nonmotor Symptoms in Dopa-Responsive Dystonia. Mov Disord Clin Pract. 2015 Jul 22;2(4):347-356.
77. Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, Beer S, Kesselring J, Stamelou M, Oertel WH, Möller JC, Lefaucheur JP. Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. Mov Disord Clin Pract. 2015 Aug 9;2(4):357-364.
78. Nalls MA, McLean CY, Rick J, et al; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 2015 Oct;14(10):1002-9.
79. Stamelou M, Diehl-Schmid J, Hapfelmeier A, Kontaxopoulou D, Stefanis L, Oertel WH, Bhatia KP, Papageorgiou SG, Höglinger GU. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 2015 Oct;21(10):1264-8
80. Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB; Parkinson's Progression Marker Initiative (PPMI) investigators.Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI). Mov Disord. 2016 Jan;31(1):79-85.
81. Stamelou M. Late-onset cerebellar ataxia: Do not forget Friedreich's. Mov Disord. 2016 Jan;31(1):7-8.
82. Papagiannakis N, Xilouri M, Koros C, Stamelou M, Antonelou R, Maniati M, Papadimitriou D, Moraitou M, Michelakakis H, Stefanis L. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. Mov Disord. 2015 Nov;30(13):1830-4.
83. Kim HJ, Stamelou M, Jeon B. Multiple system atrophy-mimicking conditions: Diagnostic challenges. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S12-5.
84. Batla A, Sánchez MC, Erro R, Ganos C, Stamelou M, Balint B, Brugger F, Antelmi E, Bhatia KP. The role of cerebellum in patients with late onset cervical/segmental dystonia?--evidence from the clinic.Parkinsonism Relat Disord. 2015 Nov;21(11):1317-22.
85. Koros C, Stamelou M. Interventions in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S93-5.
86. Respondek G, Höglinger GU, Stamelou M. From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link.Mov Disord. 2015 Dec;30(14):1871-2.
87. Gardiner AR, Jaffer F, Dale RC, Labrum R, Erro R, Meyer E, Xiromerisiou G, Stamelou M, Walker M, Kullmann D, Warner T, Jarman P, Hanna M, Kurian MA, Bhatia KP, Houlden H. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. 2015 Dec;138(Pt 12):3567-80.
88. Balint B, Stamelou M. The Discovery of Central Nervous System Lymphatic Vessels: The Missing Link That Closes the Circle of Brain Immunosurveillance Mov Disord Clin Pract. 2015 Nov 27;3(1):29-30.
89. Batla A, Stamelou M. Primary familial brain calcification in the IBGC2 kindred: All linkage roads lead to SLC20A2. Mov Disord. 2016 Dec;31(12):1765-1766
90. Huppertz HJ, Möller L, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Respondek G, Stamelou M, Schnitzler A, Pinkhardt EH, Oertel WH, Knake S, Kassubek J, Höglinger GU. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord. 2016 Oct;31(10):1506-1517.
91. Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-León J, Bhatia KP, Deuschl G, Forjaz MJ, Hallett M, Louis ED, Lyons KE, Mestre TA, Raethjen J, Stamelou M, Tan EK, Testa CM, Elble RJ. Transducer-based evaluation of tremor. Mov Disord. 2016 Sep;31(9):1327-36.
92. Stamelou M, Bhatia KP. Atypical parkinsonism - new advances. Curr Opin Neurol. 2016 Aug;29(4):480-5.
93. Stamelou M, Höglinger G. A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs. 2016 Jul;30(7):629-36.
94. Papadimitriou D, Antonelou R, Miligkos M, Maniati M, Papagiannakis N, Bostantjopoulou S, Leonardos A, Koros C, Simitsi A, Papageorgiou SG, Kapaki E, Alcalay RN, Papadimitriou A, Athanassiadou A, Stamelou M, Stefanis L. Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. Mov Disord. 2016 Aug;31(8):1226-30
95. Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU; AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord. 2016 May;31(5):742-7.
96. Ganos C, Crowe B, Stamelou M, Kresojević N, Lukić MJ, Bras J, Guerreiro R, Taiwo F, Balint B, Batla A, Schneider SA, Erro R, Svetel M, Kostić V, Kurian MA, Bhatia KP. The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism Relat Disord. 2016 Mar;24:20-7.
97. Mylius V, Pee S, Pape H, Teepker M, Stamelou M, Eggert K, Lefaucheur JP, Oertel WH, Möller JC. Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage. Eur J Pain. 2016 Sep;20(8):1223-8.
98. Valadas A, Contarino MF, Albanese A, Bhatia KP, Falup-Pecurariu C, Forsgren L, Friedman A, Giladi N, Hutchinson M, Kostic VS, Krauss JK, Lokkegaard A, Marti MJ, Milanov I, Pirtosek Z, Relja M, Skorvanek M, Stamelou M, Stepens A, Tamás G, Taravari A, Tzoulis C, Vandenberghe W, Vidailhet M, Ferreira JJ, Tijssen MA. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. Eur J Neurol. 2016 Apr;23(4):772-9
99. Batla A, Pareés I, Edwards MJ, Stamelou M, Bhatia KP, Panicker JN. Lower urinary tract dysfunction in patients with functional movement disorders. J Neurol Sci. 2016 Feb 15;361:192-4.
100. Respondek G, Kurz C, Arzberger T, Compta Y,.., Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017 Jul;32(7):995-1005
101. Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord. 2017 Jul;32(7):955-971
102. Höglinger GU, Respondek G, Stamelou M, et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017 Jun;32(6):853-864.
103. Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ; AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Mov Disord. 2017 Jun;32(6):842-852.
104. Hirschbichler ST, Erro R, Ganos C, Stamelou M, Batla A, Balint B, Bhatia KP. "Atypical" atypical parkinsonism: Critical appraisal of a cohort. Parkinsonism Relat Disord. 2017 Apr;37:36-42.
105. Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, Möller F, Schnitzler A, Oertel WH, Knake S, Huppertz HJ, Höglinger GU. Manual MRI morphometry in Parkinsonian syndromes. Mov Disord. 2017 May;32(5):778-782.
106. Obeso JA, Jon Stoessl A, Stamelou M. Editors' Note: The 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Jan;32(1):1.
107. Boura E, Stamelou M, Vadasz D, Ries V, Unger MM, Kägi G, Oertel WH, Möller JC, Mylius V. Is increased spinal nociception another hallmark for Parkinson's disease? J Neurol. 2017 Mar;264(3):570-575.
108. Bougea A, Koros C, Stamelou M, Simitsi A, Papagiannakis N, Antonelou R, Papadimitriou D, Breza M, Tasios K, Fragkiadaki S, Geronicola Trapali X, Bourbouli M, Koutsis G, Papageorgiou SG, Kapaki E, Paraskevas GP, Stefanis L. Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism Relat Disord. 2017 Feb;35:82-87.
109. Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, Espay AJ, Fung V, Garcia-Ruiz PJ, Gershanik O, Jankovic J, Kaji R, Kotschet K, Marras C, Miyasaki JM, Morgante F, Munchau A, Pal PK, Rodriguez Oroz MC, Rodríguez-Violante M, Schöls L, Stamelou M, Tijssen M, Uribe Roca C, de la Cerda A, Gatto EM; International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders. Treatable inherited rare movement disorders. Mov Disord. 2018 Jan;33(1):21-35.
110. Darling A, Tello C, Martí MJ, Garrido C, Aguilera-Albesa S, Tomás Vila M, Gastón I, Madruga M, González Gutiérrez L, Ramos Lizana J, Pujol M, Gavilán Iglesias T, Tustin K, Lin JP, Zorzi G, Nardocci N, Martorell L, Lorenzo Sanz G, Gutiérrez F, García PJ, Vela L, Hernández Lahoz C, Ortigoza Escobar JD, Martí Sánchez L, Moreira F, Coelho M, Correia Guedes L, Castro Caldas A, Ferreira J, Pires P, Costa C, Rego P, Magalhães M, Stamelou M, Cuadras Pallejà D, Rodríguez-Blazquez C, Martínez-Martín P, Lupo V, Stefanis L, Pons R, Espinós C, Temudo T, Pérez Dueñas B. Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. Mov Disord. 2017 Nov;32(11):1620-1630
111. Bhatia KP, Stamelou M. Nonmotor Features in Atypical Parkinsonism. Int Rev Neurobiol. 2017;134:1285-1301.
112. Mandemakers W, Quadri M, Stamelou M, Bonifati V. TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease? Mov Disord. 2017 Aug;32(8):1159-1162
113. Bhatia KP, Chaudhuri KR, Stamelou M. Preface. Int Rev Neurobiol. 2017;132
114. Schreglmann SR, Bhatia KP, Stamelou M. Advances in the Clinical Differential Diagnosis of Parkinson's Disease. Int Rev Neurobiol. 2017;132:79-127.
115. Erro R, Stamelou M. The Motor Syndrome of Parkinson's Disease.Int Rev Neurobiol. 2017;132:25-32
116. Carecchio M, Mencacci NE, Iodice A, Pons R, Panteghini C, Zorzi G, Zibordi F, Bonakis A, Dinopoulos A, Jankovic J, Stefanis L, Bhatia KP, Monti V, R'Bibo L, Veneziano L, Garavaglia B, Fusco C, Wood N, Stamelou M*, Nardocci N*. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients.. Parkinsonism Relat Disord. 2017 Aug;41:37-43
117. Simitsi A, Koros C, Moraitou M, Papagiannakis N, Antonellou R, Bozi M, Angelopoulou E, Stamelou M, Michelakakis H, Stefanis L. Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population.J Parkinsons Dis. 2018;8(1):101-105.
118. Koros C,* Stamelou M,* Simitsi A, Beratis I, Papadimitriou D, Papagiannakis N, Fragkiadaki S, Kontaxopoulou D, Papageorgiou SG, Stefanis L. Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Neurology. 2018 Mar 6;90(10):e864-e869.
119. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, Testa CM, Deuschl G; Tremor Task Force of the International Parkinson and Movement Disorder Society. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 Jan;33(1):75-87
120. Papagiannakis N, Koros C, Stamelou M, Simitsi AM, Maniati M, Antonelou R, Papadimitriou D, Dermentzaki G, Moraitou M, Michelakakis H, Stefanis L. Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease.Neurosci Lett. 2018 Apr 13;672:145-149.
121. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep;32(9):1264-1310
122. Borm CDJM, Krismer F, Wenning GK, Seppi K, Poewe W, Pellecchia MT, Barone P, Johnsen EL, Østergaard K, Gurevich T, Djaldetti R, Sambati L, Cortelli P, Petrović I, Kostić VS, Brožová H, Růžička E, Marti MJ, Tolosa E, Canesi M, Post B, Nonnekes J, Bloem BR; European MSA Study Group (EMSA-SG). Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism Relat Disord. 2018 Jun 8123. Ricciardi L, Edwards MJ, Fasano A, Bhatia KP, Stamelou M. Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: what's in a phenotype? J Neurol Sci. 2018 Jul 15;390:84-86.
124. Stamelou M, Petrucci S, Ginevrino M, Pons R, Papagiannakis N, Stefanis L, Valente EM. Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. J Neurol Sci. 2018 May 15;388:158
125. Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D, Kontaxopoulou D, Fragkiadaki S, Papagiannakis N, Seibyl J, Marek K, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease. Mov Disord. 2018 Oct 4
126. Giagkou N, Stamelou M. Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. CNS Drugs. 2018 Sep;32(9):827-837.
127. Latorre A, Rocchi L, Stamelou M, Batla A, Ciocca M, Balint B, Sidle K, Berardelli A, Rothwell JC, Bhatia KP. Tremor in motor neuron disease may be central rather than peripheral in origin. Eur J Neurol. 2018 Jun 28.
128. Maraki MI, Yannakoulia M, Stamelou M, Stefanis L, Xiromerisiou G, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Anastasiou CA, Simopoulou E, Scarmeas N.Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Mov Disord. 2018 Oct 10.
129. Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2018 Sep 4
130. Marek K, Chowdhury S, Siderowf A, Parkinson's Progression Markers Initiative. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
131. Ramos EM, Koros C, Dokuru DR, Van Berlo V, Kroupis C, Wojta K, Wang Q, Andronas N, Matsi S, Beratis IN, Huang AY, Lee SE, Bonakis A, Florou-Hatziyiannidou C, Fragkiadaki S, Kontaxopoulou D, Agiomyrgiannakis D, Kamtsadeli V, Tsinia N, Papastefanopoulou V, Stamelou M, et al. Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. Neurobiol Aging. 2019 Mar;75:224.
132. Marek K, Chowdhury S,; Parkinson's Progression Markers Initiative. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
133. Grimm MJ, Respondek G, Stamelou M, et al. Movement Disorder Society-endorsed PSP Study Group.How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019 Mar 18. doi: 10.1002/mds.27666. [Epub ahead of print]
134. Balint B, Charlesworth G, Stamelou M, Carr L, Mencacci NE, Wood NW, Bhatia KP Mitochondrial complex I NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy. Eur J Neurol. 2019 Mar 21. doi: 10.1111/ene.13956. [Epub ahead of print]
135. Ebrahimi-Fakhari D, Münchau A, Stamelou M. A special issue on childhood-onset movement disorders. Mov Disord. 2019 May;34(5):595-597.
136. Bougea A, Maraki MI, Yannakoulia M, Stamelou M, et al. Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology. 2019 May 7;92(19):e2261-e2272.
137. Papagiannakis N, Xilouri M, Koros C, Simitsi AM, Stamelou M, Maniati M, Stefanis L. Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson's disease patients. Neurosci Lett. 2019 Jun 21;704:112-115.
138. Giagkou N, Stamelou M. Emerging drugs for progressive supranuclear palsy. Expert Opin Emerg Drugs. 2019 Jun;24(2):83-92.
139. Martinez-Martin P, Radicati FG, Rodriguez Blazquez C, Wetmore J, Kovacs N, Ray Chaudhuri K, Stocchi F; PDCS European Study Group. Extensive validation study of the Parkinson's Disease Composite Scale. Eur J Neurol. 2019 Apr 25. doi: 10.1111/ene.13976. [Epub ahead of print]
140. Stankovic I, Quinn N, Vignatelli L, Antonini A, Berg D, Coon E, Cortelli P, Fanciulli A, Ferreira JJ, Freeman R, Halliday G, Höglinger GU, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Lang A, Levin J, Low P, Mathias C, Meissner WG, Kaufmann LN, Palma JA, Panicker JN, Pellecchia MT, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK; Movement Disorder Society Multiple System Atrophy Study Group. A critique of the second consensus criteria for multiple system atrophy. Mov Disord. 2019 Jul;34(7):975-984.
141. Popkirov S, Nicholson TR, Bloem BR, Cock HR, Derry CP, Duncan R, Dworetzky BA, Edwards MJ, Espay AJ, Hallett M, Lang AE, Leach JP, Lehn A, McGonigal A, Morgante F, Perez DL, Reuber M, Richardson MP, Smith P, Stamelou M, Tijssen MAJ, Tinazzi M, Carson AJ, Stone J. Hiding in Plain Sight: Functional Neurological Disorders in the News. J Neuropsychiatry Clin Neurosci. 2019 May 23: doi: 10.1176/appi.neuropsych.19010025. [Epub ahead of print]
142. Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019 Aug;18(8):748-759.
143. Stamelou M. Neuroprotection in multiple system atrophy: unresolved issues. Lancet Neurol. 2019 Aug;18(8):710-711.
144. Stamelou M, Giagkou N, Höglinger GU. One decade ago, one decade ahead in progressive supranuclear palsy. Mov Disord. 2019 Jul 8. doi: 10.1002/mds.27788. [Epub ahead of print]
145. Maraki MI, Stefanis L, Yannakoulia M, Kosmidis MH, Xiromerisiou G, Dardiotis E, Hadjigeorgiou GM, Sakka P, Scarmeas N, Stamelou M. Motor function and the probability of prodromal Parkinson's disease in older adults. Mov Disord. 2019 Jul 17. doi: 10.1002/mds.27792. [Epub ahead of print]
146. Stamelou M. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord. 2019 Aug;34(8):1087-1088.
147. Angelopoulou E, Bozi M, Simitsi AM, Koros C, Antonelou R, Papagiannakis N, Maniati M, Poula D, Stamelou M, et al. The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism Relat Disord. 2019 Aug 26. [Epub ahead of print]
148. Respondek G, Grimm MJ, Piot I, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27872. [Epub ahead of print]
149. Mulroy E, Stamelou M, Bhatia KP. How to approach a patient with parkinsonism - red flags for atypical parkinsonism. Int Rev Neurobiol. 2019;149:1-34. doi: 10.1016/bs.irn.2019.10.001.
150. Giagkou N, Bhatia KP, Höglinger GU, Stamelou M.Genetic mimics of the non-genetic atypical parkinsonian disorders - the 'atypical' atypical. Int Rev Neurobiol. 2019;149:327-351. doi: 10.1016/bs.irn.2019.10.008.
151. Respondek G, Stamelou M, Höglinger GU.Classification of atypical parkinsonism per pathology versus phenotype. Int Rev Neurobiol. 2019;149:37-47. doi: 10.1016/bs.irn.2019.10.003.
152. Giagkou N, Höglinger GU, Stamelou M. Progressive supranuclear palsy. Int Rev Neurobiol. 2019;149:49-86. doi: 10.1016/bs.irn.2019.10.013.153. Balestrino R, Hurtado-Gonzalez CA, Stocchi ; PDCS European Study Group. Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). NPJ Parkinsons Dis. 2019 Nov 27;5:26. doi: 10.1038/s41531-019-0097-1.
154. Piot I, Schweyer K, Respondek G, Stamelou M; DescribePSP study group; ProPSP study group; MDS-endorsed PSP study group, Sckopke P, Schenk T, Goetz CG, Stebbins GT, Höglinger GU. The Progressive Supranuclear Palsy Clinical Deficits Scale. Mov Disord. 2020 Jan 17. doi: 10.1002/mds.27964. Online ahead of print.
155. Ravanidis S, Bougea A, Papagiannakis N, Maniati M, Koros C, Simitsi AM, Bozi M, Pachi I, Stamelou M, Paraskevas GP, Kapaki E, Moraitou M, Michelakakis H, Stefanis L, Doxakis E. Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease. Mov Disord. 2020 Mar;35(3):457-467. doi: 10.1002/mds.27928.
156. Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Pachi I, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. J Parkinsons Dis. 2020 Mar 11. doi: 10.3233/JPD-191860.